nosyl-5-methylcytosine (1, 8, 11) , and 5-ethyl-, 5-vinyl-, 5-propyl-and 5-allyl-2'-deoxyuridine (3, 7, 10) , have been shown to inhibit the replication of herpes simplex virus (or varicella-zoster virus [9] ) at doses which did not adversely affect the growth of the (uninfected) host cells. Whereas 5-iodo-2'-deoxycytidine, 5 -bromo-2'-deoxycytidine, 5-ethyl-2'-deoxyuridine, and 1-fl-D-arabinofuranosylthymine were also reported as being active against vaccinia virus (7, 8, 15, 16) , other TdR analogs such as 5-iodo-5'-amino-2'-5'-dideoxyuridine (14) , 5-methylamino-and 5-methoxymethyl-2'-deoxyuridine (2, 18) proved specifically active against herpes simplex virus.
Here we report that 5-propyl-2'-deoxyuridine (PrUdR) inhibits the replication of herpes simplex type 1 virus (strain KOS) at a concentration that is at least 200 times lower than that required to inhibit other deoxyribonucleic acid (DNA) viruses such as vaccinia virus and to suppress cellular DNA synthesis. Accordingly, PrUdR, the antiviral properties of which were first mentioned by Gauri and Malorny (10) , could be considered as a selective inhibitor of herpes simplex virus.
PrUdR was synthesized in a manner analogous to that of 5-ethyl-2'-deoxyuridine (EtUdR), previously described (19) , starting with 5-propyluracil kindly supplied by B. Fiszer. The product was recrystallized from ethanol in the form of needles, mp 169°C (uncorrected). Its ultraviolet absorption spectrum in aqueous medium at neutral and alkaline pH was similar to that of thymidine and EtUdR. The same compound has been prepared by Cheng et (Table 1) . In contrast to PrUdR, the reference materials IUdR, ara-C, and ara-A inhibited cellular DNA synthesis at concentrations that were not far in excess ofthose required to inhibit virus replication (Table 1) .
To ascertain that the inhibitory effects of PrUdR on viral cytopathogenicity actually reflected an inhibition of viral multiplication, vaccinia and herpes simplex virus growth were determined in cell cultures that had been exposed to PrUdR immediately after virus inoculation (Fig. 1) PRK (vaccinia) or VERO (herpes sgmplex) ceU cultures. Symbols: 0, control; 0, PrUdR (100 pg/ml); A, IUdR (10 pg/ml).
causing 30% inhibition of (PRK) cell proliferation, the antiviral indexes were: >300 for PrUdR, 100 for EtUdR, and 20 for IUdR (E. De Clercq, J. Descamps, P. F. Torrence, E. Krajewska, and D. Shugar, 10th Int. Cong. of Chemother., Zuirich, Switzerland, September 18-23, Abstr. no. 450, 1977). Thus, PrUdR appears to exhibit a significantly greater safety margin (at least in PRK cell cultures) than the established antiviral drugs IUdR, ara-C, and ara-A.
The minimum concentration at which PrUdR was found effective in inhibitng herpes implex type 1 (stain KOS) in PRK and HSF cell cultures (1 pig/ml) closely coresponds to the mini-
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on January 12, 2018 by guest http://aac.asm.org/ Downloaded from VOL. 13, 1978 mum concentration (-3 pM) at which PrUdR inhibited herpes simplex virus replication in HeLa cells (3). However, in these previous studies (3) it was not assessed whether PrUdR was effective against viruses other than herpes simplex.
The mechanism by which PrUdR exerts its selective anti-herpes action remains to be unravelled. PrUdR may specifically inhibit one or another enzyme that is coded for by the virus. As noted previously for other TdR analogs (6), the anti-herpes activity of PrUdR depends on the presence of a virus-induced TdR kinase in the infected cell. PrUdR was efficacious against herpes simplex type 1 strain KOS, a virus that induces TdR kinase activity in both PRK and HSF cell cultures (6) 
